These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

346 related items for PubMed ID: 24798623

  • 1. Von Willebrand factor antigen for detection of hepatopulmonary syndrome in patients with cirrhosis.
    Horvatits T, Drolz A, Roedl K, Herkner H, Ferlitsch A, Perkmann T, Müller C, Trauner M, Schenk P, Fuhrmann V.
    J Hepatol; 2014 Sep; 61(3):544-9. PubMed ID: 24798623
    [Abstract] [Full Text] [Related]

  • 2. von Willebrand factor as new noninvasive predictor of portal hypertension, decompensation and mortality in patients with liver cirrhosis.
    Ferlitsch M, Reiberger T, Hoke M, Salzl P, Schwengerer B, Ulbrich G, Payer BA, Trauner M, Peck-Radosavljevic M, Ferlitsch A.
    Hepatology; 2012 Oct; 56(4):1439-47. PubMed ID: 22532296
    [Abstract] [Full Text] [Related]

  • 3. Von Willebrand factor levels predict clinical outcome in patients with cirrhosis and portal hypertension.
    La Mura V, Reverter JC, Flores-Arroyo A, Raffa S, Reverter E, Seijo S, Abraldes JG, Bosch J, García-Pagán JC.
    Gut; 2011 Aug; 60(8):1133-8. PubMed ID: 21427197
    [Abstract] [Full Text] [Related]

  • 4. Hepatopulmonary syndrome: prevalence and predictors in Egyptian cirrhotic patients.
    El Makarem MA, Elakad A, Ali A, Abd-Elkader M, Sayed AF, Taha A, Abd-Elrhman T.
    Trop Gastroenterol; 2011 Aug; 32(1):25-30. PubMed ID: 21922852
    [Abstract] [Full Text] [Related]

  • 5. Von-Willebrand factor as a predictor of three-month mortality in patients with liver cirrhosis compared to MELD score.
    Curakova Ristovska E, Genadieva-Dimitrova M, Caloska-Ivanova V, Misevski J.
    Acta Gastroenterol Belg; 2019 Aug; 82(4):487-493. PubMed ID: 31950803
    [Abstract] [Full Text] [Related]

  • 6. von Willebrand factor as a novel noninvasive predictor of portal hypertension and esophageal varices in hepatitis B patients with cirrhosis.
    Wu H, Yan S, Wang G, Cui S, Zhang C, Zhu Q.
    Scand J Gastroenterol; 2015 Aug; 50(9):1160-9. PubMed ID: 25877661
    [Abstract] [Full Text] [Related]

  • 7. High plasma levels of von Willebrand factor as a marker of endothelial perturbation in cirrhosis: relationship to endotoxemia.
    Ferro D, Quintarelli C, Lattuada A, Leo R, Alessandroni M, Mannucci PM, Violi F.
    Hepatology; 1996 Jun; 23(6):1377-83. PubMed ID: 8675154
    [Abstract] [Full Text] [Related]

  • 8. Pulse oximetry is insufficient for timely diagnosis of hepatopulmonary syndrome in children with liver cirrhosis.
    Hoerning A, Raub S, Neudorf U, Müntjes C, Kathemann S, Lainka E, Stehling F, Hoyer PF, Gerner P.
    J Pediatr; 2014 Mar; 164(3):546-52.e1-2. PubMed ID: 24321540
    [Abstract] [Full Text] [Related]

  • 9. A study of hepatopulmonary syndrome among patients of cirrhosis of liver and portal hypertension.
    Hira HS, Kumar J, Tyagi SK, Jain SK.
    Indian J Chest Dis Allied Sci; 2003 Mar; 45(3):165-71. PubMed ID: 12866633
    [Abstract] [Full Text] [Related]

  • 10. Screening of hepatopulmonary syndrome (HPS) with CEUS and pulse-oximetry in liver cirrhosis patients eligible for liver transplant.
    Suceveanu AI, Mazilu L, Tomescu D, Ciufu N, Parepa IR, Suceveanu AP.
    Chirurgia (Bucur); 2013 Mar; 108(5):684-8. PubMed ID: 24157113
    [Abstract] [Full Text] [Related]

  • 11. The VITRO Score (Von Willebrand Factor Antigen/Thrombocyte Ratio) as a New Marker for Clinically Significant Portal Hypertension in Comparison to Other Non-Invasive Parameters of Fibrosis Including ELF Test.
    Hametner S, Ferlitsch A, Ferlitsch M, Etschmaier A, Schöfl R, Ziachehabi A, Maieron A.
    PLoS One; 2016 Mar; 11(2):e0149230. PubMed ID: 26895398
    [Abstract] [Full Text] [Related]

  • 12. [Hepatopulmonary syndrome in liver cirrhosis].
    Culafić Dj, Perisić M, Rebić P.
    Srp Arh Celok Lek; 2000 Mar; 128(7-8):271-5. PubMed ID: 11089435
    [Abstract] [Full Text] [Related]

  • 13. von Willebrand factor and procoagulant imbalance predict outcome in patients with cirrhosis and thrombocytopenia.
    Kalambokis GN, Oikonomou A, Christou L, Kolaitis NI, Tsianos EV, Christodoulou D, Baltayiannis G.
    J Hepatol; 2016 Nov; 65(5):921-928. PubMed ID: 27297911
    [Abstract] [Full Text] [Related]

  • 14. Pulmonary vascular abnormalities in cirrhosis.
    Herve P, Le Pavec J, Sztrymf B, Decante B, Savale L, Sitbon O.
    Best Pract Res Clin Gastroenterol; 2007 Nov; 21(1):141-59. PubMed ID: 17223502
    [Abstract] [Full Text] [Related]

  • 15. Schistosomiasis and hepatopulmonary syndrome: the role of concomitant liver cirrhosis.
    Gonçalves-Macedo L, Lopes EP, Domingues ALC, Markman B, Mota VG, Luna CF.
    Mem Inst Oswaldo Cruz; 2017 Jul; 112(7):469-473. PubMed ID: 28591307
    [Abstract] [Full Text] [Related]

  • 16. Response of von Willebrand factor parameters to desmopressin in patients with type 1 and type 2 congenital von Willebrand disease: diagnostic and therapeutic implications.
    Michiels JJ, van de Velde A, van Vliet HH, van der Planken M, Schroyens W, Berneman Z.
    Semin Thromb Hemost; 2002 Apr; 28(2):111-32. PubMed ID: 11992235
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Frequency of hepatopulmonary syndrome in cirrhotic patients.
    Shafiq M, Khan AA, Alam A, Butt AK, Shafqat F, Malik K, Amin J, Hassan W.
    J Coll Physicians Surg Pak; 2008 May; 18(5):278-81. PubMed ID: 18541081
    [Abstract] [Full Text] [Related]

  • 19. Von Willebrand factor indicates bacterial translocation, inflammation, and procoagulant imbalance and predicts complications independently of portal hypertension severity.
    Mandorfer M, Schwabl P, Paternostro R, Pomej K, Bauer D, Thaler J, Ay C, Quehenberger P, Fritzer-Szekeres M, Peck-Radosavljevic M, Trauner M, Reiberger T, Ferlitsch A, Vienna Hepatic Hemodynamic Lab.
    Aliment Pharmacol Ther; 2018 Apr; 47(7):980-988. PubMed ID: 29377193
    [Abstract] [Full Text] [Related]

  • 20. The Addition of C-Reactive Protein and von Willebrand Factor to Model for End-Stage Liver Disease-Sodium Improves Prediction of Waitlist Mortality.
    Starlinger P, Ahn JC, Mullan A, Gyoeri GP, Pereyra D, Alva-Ruiz R, Hackl H, Reiberger T, Trauner M, Santol J, Simbrunner B, Mandorfer M, Berlakovich G, Kamath PS, Heimbach J.
    Hepatology; 2021 Sep; 74(3):1533-1545. PubMed ID: 33786862
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.